linjc16/ctgov huggingface dataset:
D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.

Official Title
-----------------
Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of d-MPH in the Treatment of Fatigue and Neurobehavioral Impairment Related to Chemotherapy in Adult Cancer Patients

Conditions
-----------------
Fatigue, Neoplasms

Intervention / Treatment
-----------------
* Drug: dexmethylphenidate(d-mph)


Participation Criteria
=================
Eligibility Criteria
-----------------
Diagnosis of cancer, excluding primary or metastatic brain tumors. Treated with a minimum of four cycles of a cytotoxic chemotherapy, the last chemotherapy treatment must have been completed at least 2 months prior to study entry. Physical/neurological examination consistent with the absence of a focal neurological deficit Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner). Subjects must be able to adhere to the protocol requirements. Subjects must understand and voluntarily sign an informed consent document. Subjects must be a native English speaker or fluent in English, and have at least an eighth grade education.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: dexmethylphenidate(d-mph)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neurobehavioral function, chemobrain, chemo brain, fatigue, memory loss, exhausted, trouble concentrating
Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients

Study Overview
=================
Brief Summary
-----------------
Our study aimed to evaluate the correlation between test reagent specific gene test results and the efficacy of relevant targeted drugs in patients with non-small cell lung cancer, and to support the continued registration of test reagents.

Official Title
-----------------
Clinical Trials to Evaluate the Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients With Non-small Cell Lung Cancer

Conditions
-----------------
Non-small Cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1)≥18，advanced non-small cell lung cancer confirmed by histopathology, and were previously or currently treated with gefitinib tablets (as the first-line treatment) or osimertinib (first-generation TKI resistance treatment) or crizotinib capsules monotherapy were evaluated for efficacy. 2) Able to provide FFPE samples with a storage life of 5 years: Large specimen 5 pieces in each case; 10 puncture specimens in each case Exclusion Criteria: 1) Pathological evaluation of the tissue sample has too few tumor cells (total number of tumor cells >20%); 2) Combination therapy with chemotherapy/radiotherapy/other targeted drugs/immunotherapy drugs; 3) Maintenance treatment when the disease does not progress after other anti-tumor treatments.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | Progression free survival time | October 2022-December 2022 | 
| ORR | Objective response rate | October 2022-December 2022 | 
| Consistency | he consistency of efficacy between specified kit and 22C3 | October 2022-December 2022 |
Registry Study of Clinical Application of MRI Compatible CIED

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to clear the Safety and Necessity of the Magnetic Resonance Imaging (MRI) in the Presence of CIEDs(Cardiovascular Implantable Electronic Devices).

Conditions
-----------------
Need for MRI Imaging With Pacemaker or Implantable Cardioverter Defibrillator Implanted

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Patient is >18 years old Patient implanted with a Biotronik MRI compatible CIED (including the pacemaker, cardiac resynchronization therapy, implantable cardioverter defibrillator, and cardiac resynchronization therapy-defibrillator) in the past two months Patient has provided a written informed consent Patient's height is≥140cm Exclusion criteria Have other medical implants that may interact with MRI, e.g. abandoned pacemaker/ICD leads, lead extensions, mechanical valves, other active medical devices, non-MRI compatible devices Life expectancy less than 2 years Pregnant and/or breat-feeding females or females who intend to become pregnant in next two years Patient is currently participating in another study In the investigator's opinion patient will not be able to comply with the follow-up requirements

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serious adverse events |  | two years | 
| The raise of Impedance Threshold of the Atrial and Ventricle |  | immediate；one month | 
| RA sensing amplitude (daily mean): < 1.5 mV or RV sensing amplitude (daily min.): < 2.0 mV |  | immediate；one month | 
| The proportion of patients with CIED who need MRI examination |  | two years |
Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine which type of food results in a shorter hospital stay and better overall outcome for babies born with gastroschisis.

Official Title
-----------------
Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair

Conditions
-----------------
Gastroschisis

Intervention / Treatment
-----------------
* Dietary Supplement: Enteral Intake - Human Milk
* Dietary Supplement: Enteral Intake - Formula


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) neonates born with gastroschisis 2) neonatologist, surgeon, and parent (or care provider) willing to have the neonate participate in the study Exclusion Criteria: 1) associated anomaly or medical concern that impacts hospital length of stay (i.e. intestinal atresia, very low birth weight(<1500 grams)) 2) known major chromosomal abnormality

Ages Eligible for Study
-----------------
Minimum Age: 2 Hours
Maximum Age: 48 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Human Milk<br>Neonates fed human milk | Dietary Supplement: Enteral Intake - Human Milk<br>* Comparing formula and human milk<br>|
| Placebo Comparator: Formula<br>Neonates fed formula | Dietary Supplement: Enteral Intake - Formula<br>* Comparing formula and human milk<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of Hospital Stay |  | One month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Full Enteral Feeds |  | Three weeks | 
| Time on Total Parenteral Nutrition |  | Three weeks |
Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to identify which ultrasonographic feature or a combination of features is the best predictor of thyroid cancer in thyroid nodules.

Official Title
-----------------
Evaluation of Thyroid Fine Needle Aspiration Biopsies: Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules

Conditions
-----------------
Thyroid Nodule

Intervention / Treatment
-----------------
* Procedure: Thyroid ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with thyroid nodules over 10 mm in the longest diameter Euthyroid or hypothyroid subjects with a solitary thyroid nodule or multinodular goiter Subjects with a hypoactive nodule in the thyroid scan and a low TSH Exclusion Criteria: Subjects with four or more thyroid nodules that are over 10 mm Subjects with low TSH and hyperactive nodule on thyroid scan

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Thyroid nodule<br>Subjects who present with thyroid nodules will be enrolled into the study. Euthyroid and hypothyroid subjects with a solitary thyroid nodule or multinodular goiter will be enrolled. For subjects with a suppressed TSH, a thyroid scan will be performed. Subjects with a hypoactive nodule in the thyroid scan and a low TSH will be enrolled. | Procedure: Thyroid ultrasonography<br>* Ultrasound-guided thyroid fine-needle aspiration biopsy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thyroid cancer |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thyroid nodule, Biopsy, Fine-Needle
A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers

Study Overview
=================
Brief Summary
-----------------
The purposes of this study are: to determine the safety and tolerability of multiple doses of A-831 at various doses to determine how multiple doses of A-831 are distributed through the bloodstream to determine if A-831 reduces the amount of Hepatitis C virus in the blood

Official Title
-----------------
A Clinical Pharmacology Study to Determine the Pharmacokinetic , Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of A-831 in Otherwise Healthy Male Hepatitis C Carriers With Compensated Liver Disease

Conditions
-----------------
Chronic Hepatitis C

Intervention / Treatment
-----------------
* Drug: A-831


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Volunteers will be males of any race aged 18-60 years with a BMI between 18 and 32 kg/m2 at the time of the screening medical Volunteers who have given their written informed consent to participate in the study Volunteers who are willing and able to comply with the protocol and study procedures Volunteers who have a diagnosis of chronic hepatitis C infection and are in good health (other than history of Hepatitis C infection) Exclusion Criteria: Voulnteers with concurrent medical conditions or taking concurrent medications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: A-831|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety |  |  | 
| PK |  |  | 
| Tolerability |  |  | 
| Antiviral activity |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HCV, antiviral, PK, Safety
Individualized Exercise Program for Treatment of Fatigue in Patients After Hematologic Stem Cell Transplant (HSCT)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the impact of fatigue in severely affected transplant patients.

Detailed Description
-----------------
Investigates impact of a monitored program in kinesiology lab at the University of Calgary on fatigue in severely affected transplant patients.

Official Title
-----------------
Individualized Exercise Program for Treatment of Fatigue in Patients After Hematologic Stem Cell Transplant

Conditions
-----------------
Fatigue

Intervention / Treatment
-----------------
* Behavioral: exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Severe fatigue post transplant Exclusion Criteria: Other conditions contributing to fatigue (graft versus host disease)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: exercise|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fatigue score |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
transplant, fatigue, exercise, Malignant disease
Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.

Study Overview
=================
Brief Summary
-----------------
Since December 2019, a new agent, the coronavirus SARS-Cov-2, has spread from China to the rest of the world causing an international epidemic of respiratory diseases called COVID-19. Oise was one of the first clusters in France, with more than 4,000 confirmed cases. A significant proportion (80%) of patients with COVID-19 are ambulatory. However, few data are available for this particular population in France. Thus, few clear recommendations are available. We propose to conduct a large cohort of observation of suspected or confirmed COVID-19 patients on an ambulatory basis in the Oise region. This observatory will make it possible to describe the epidemiological characteristics and initial management of COVID-19 patients and to identify early severity factors.

Official Title
-----------------
Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.

Conditions
-----------------
Covid-19

Intervention / Treatment
-----------------
* Other: observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with covid 19 symptoms patients who had a contact with a person PCR Covid 19+ Exclusion Criteria: none

Ages Eligible for Study
-----------------
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| outpatients COVID 19 positive<br> | Other: observational<br>* observational management of outpatients COVID 19<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical description of covid 19 ambulatory cases. |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biological and radiological description of ambulatory cases |  | 3 months | 
| Prevalence of positive cases (PCR and/or serological positive) |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ambulatory, outpatients, COVID 19, Oise, France
Patient Preference and Visual Quality With Contralateral Synergy Versus Panoptix

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to compare the visual quality and patient preference of the Synergy IOL versus the PanOptix IOL when one of each lens is placed in the same patient.

Official Title
-----------------
Patient Preference and Visual Quality With Contralateral Synergy Versus Panoptix

Conditions
-----------------
IOL, Cataract, Patient Satisfaction

Intervention / Treatment
-----------------
* Device: TECNIS Synergy IOL
* Device: AcrySof PanOptix Trifocal IOL


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Bilateral cataracts for which phacoemulsification extraction and posterior IOL implantation have been planned for both eyes Desire to mitigate postoperative presbyopia with implantation of Synergy IOL in one eye and PanOptix Trifocal IOL in the opposite eye Exclusion Criteria: Any vision-limiting problems (e.g., corneal, retinal, infection) which can potentially limit post-operative visual performance Any ocular condition or trauma that is not resolved, stable, or would compromise the well-being of the subject

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: TECNIS Synergy IOL|Implanted in one eye|
|Device: AcrySof PanOptix Trifocal IOL|Implanted in one eye|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Satisfaction - subjective questionnaire | Subjective questionnaire explores the frequency and need for glasses for various visual functions at distance, intermediate, and near and overall satisfaction of visual function without glasses | 3 months to 18 months after cataract surgery | 
| Visual Acuity at Distance | Uncorrected and best corrected visual acuities measured at distance | 3 months to 18 months after cataract surgery | 
| Visual Acuity at Intermediate | Uncorrected and best corrected visual acuities measured at intermediate | 3 months to 18 months after cataract surgery | 
| Visual Acuity at Near | Uncorrected and best corrected visual acuities measured at near | 3 months to 18 months after cataract surgery |
Diet Quality and LTL in NHANES

Study Overview
=================
Brief Summary
-----------------
In our study, we used data from 4,758 healthy adults from the 1999-2002 National Health and Nutrition Examination Surveys to examine the associations between evidence-based diet quality indices and leukocyte telomere length. Our study assessed the four most widely recognized and commonly used diet quality indices in nutritional epidemiology: the USDA-developed Healthy Eating Index-2010, the Alternate Healthy Eating Index-2010, the Mediterranean Diet Score, and the DASH diet score. Analyses were adjusted for sociodemographic and health variables known to influence dietary intake and cellular aging.

Official Title
-----------------
Diet Quality Indices and Leukocyte Telomere Length Among Healthy US Adults: Data From the National Health and Nutrition Examination Surveys (NHANES) 1999-2002

Conditions
-----------------
Telomere Length, Mean Leukocyte, Diet Habit

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 20 to 65 years No prior diagnosis of major chronic disease (coronary heart disease, angina, myocardial infarction, stroke, diabetes, congestive heart failure, and cancer) Exclusion Criteria: Prior diagnosis of major chronic disease (coronary heart disease, angina, myocardial infarction, stroke, diabetes, congestive heart failure, and cancer) Younger than age 20 or older than age 65

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Leukocyte telomere length |  | 1999-2002 |